ZA201408149B - Parenteral esmolol formulation - Google Patents

Parenteral esmolol formulation

Info

Publication number
ZA201408149B
ZA201408149B ZA2014/08149A ZA201408149A ZA201408149B ZA 201408149 B ZA201408149 B ZA 201408149B ZA 2014/08149 A ZA2014/08149 A ZA 2014/08149A ZA 201408149 A ZA201408149 A ZA 201408149A ZA 201408149 B ZA201408149 B ZA 201408149B
Authority
ZA
South Africa
Prior art keywords
esmolol formulation
parenteral
parenteral esmolol
formulation
esmolol
Prior art date
Application number
ZA2014/08149A
Other languages
English (en)
Inventor
Widmann Rudolf
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201408149(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of ZA201408149B publication Critical patent/ZA201408149B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2014/08149A 2012-05-10 2014-11-07 Parenteral esmolol formulation ZA201408149B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167443 2012-05-10
PCT/EP2013/059594 WO2013167657A1 (en) 2012-05-10 2013-05-08 Parenteral esmolol formulation

Publications (1)

Publication Number Publication Date
ZA201408149B true ZA201408149B (en) 2016-08-31

Family

ID=48407551

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/08149A ZA201408149B (en) 2012-05-10 2014-11-07 Parenteral esmolol formulation

Country Status (27)

Country Link
US (3) US20150087704A1 (enExample)
EP (1) EP2846776B1 (enExample)
JP (1) JP6220383B2 (enExample)
CN (1) CN104379134A (enExample)
AU (1) AU2013258031B2 (enExample)
BR (1) BR112014027870B1 (enExample)
CA (1) CA2872953C (enExample)
CL (1) CL2014003028A1 (enExample)
DK (1) DK2846776T3 (enExample)
EA (1) EA032344B1 (enExample)
ES (1) ES2794093T3 (enExample)
HR (1) HRP20200897T1 (enExample)
HU (1) HUE049314T2 (enExample)
IL (1) IL235497A0 (enExample)
LT (1) LT2846776T (enExample)
MA (1) MA37500B1 (enExample)
MX (1) MX374771B (enExample)
MY (1) MY173900A (enExample)
NZ (1) NZ701429A (enExample)
PH (1) PH12014502494B1 (enExample)
PL (1) PL2846776T3 (enExample)
PT (1) PT2846776T (enExample)
SI (1) SI2846776T1 (enExample)
TN (1) TN2014000464A1 (enExample)
UA (1) UA115333C2 (enExample)
WO (1) WO2013167657A1 (enExample)
ZA (1) ZA201408149B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122157A1 (en) * 2017-12-21 2019-06-27 Ipsol Ag A lyophilisate comprising esmolol and adenosine for use in cardioplegia
CN111848420A (zh) * 2020-07-22 2020-10-30 杭州煌森生物科技有限公司 一种盐酸艾司洛尔的新晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2007026771A1 (ja) * 2005-08-31 2007-03-08 Ono Pharmaceutical Co., Ltd. 点滴用注射剤
US20080293814A1 (en) 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
NZ586200A (en) 2007-12-21 2012-06-29 Aop Orphan Pharmaceuticals Ag Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
CN102106846A (zh) * 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法

Also Published As

Publication number Publication date
MX2014013556A (es) 2015-01-16
IL235497A0 (en) 2014-12-31
PT2846776T (pt) 2020-05-28
DK2846776T3 (da) 2020-06-15
NZ701429A (en) 2016-04-29
AU2013258031A1 (en) 2014-11-20
MA37500A1 (fr) 2016-03-31
US20150087704A1 (en) 2015-03-26
CA2872953C (en) 2020-04-07
PH12014502494A1 (en) 2015-01-12
BR112014027870A8 (pt) 2023-01-17
MA37500B1 (fr) 2016-12-30
EP2846776B1 (en) 2020-04-15
MY173900A (en) 2020-02-26
US11963940B2 (en) 2024-04-23
CA2872953A1 (en) 2013-11-14
EA201491841A1 (ru) 2015-02-27
HRP20200897T1 (hr) 2020-11-27
US20220249424A1 (en) 2022-08-11
MX374771B (es) 2025-03-06
EP2846776A1 (en) 2015-03-18
PH12014502494B1 (en) 2019-11-13
BR112014027870A2 (pt) 2017-06-27
JP2015520142A (ja) 2015-07-16
PL2846776T3 (pl) 2020-09-21
CL2014003028A1 (es) 2015-06-19
UA115333C2 (uk) 2017-10-25
BR112014027870B1 (pt) 2023-04-25
EA032344B1 (ru) 2019-05-31
AU2013258031B2 (en) 2017-08-03
TN2014000464A1 (en) 2016-03-30
SI2846776T1 (sl) 2020-08-31
LT2846776T (lt) 2020-06-25
JP6220383B2 (ja) 2017-10-25
WO2013167657A1 (en) 2013-11-14
CN104379134A (zh) 2015-02-25
US20170326095A1 (en) 2017-11-16
HUE049314T2 (hu) 2020-09-28
HK1204265A1 (en) 2015-11-13
ES2794093T3 (es) 2020-11-17

Similar Documents

Publication Publication Date Title
DK3327112T3 (en) Agse-deficient stamme
DK2830816T3 (en) Hidtil ukendt coatingkoncept
ZA201503358B (en) Structure
EP2935220A4 (en) PERI-carbinol
GB201411223D0 (en) None
GB201319035D0 (en) Spolier structure
IL236699B (en) Carbamate-benzoxazinones
PL2873355T3 (pl) Komponent podstawowy
GB201903206D0 (en) n
HUP1300640A2 (en) Belt-mounting structure
AU343908S (en) Stand
PL2537707T3 (pl) Poziome urządzenie blokujące do ryglowania kontenera
IL237041A0 (en) A medical preparation of rasagiline which is not released in the intestines
EP2871919A4 (en) STRUCTURE
IL233171A0 (en) A derivative of sitaxantan
ZA201408149B (en) Parenteral esmolol formulation
GB2503675B (en) Brackets
GB201223266D0 (en) Glycopolymers
GB201211545D0 (en) Assassin
AU344854S (en) Stand
AU343386S (en) Stand
GB201208073D0 (en) Support
TWM433068U (en) Stand structure
EP2935308A4 (en) POLYMORPH
GB201410091D0 (en) None